[New therapeutic approaches in glioblastomas].
Current treatment of glioblastomas relies on surgical resection, radiotherapy and chemotherapy. However, the efficacy of these therapeutics is still limited and new therapeutic approaches based on the understanding of brain tumor biology are emerging. High expression of the EGF receptor by tumor cells, activation of the PI3K/Akt and the Ras/Raf pathways represent interesting targets for new selective drugs under development. The most promising drugs are currently antiangiogenic agents. This article reviews these emerging therapies currently under clinical trials in glioblastomas.
Le Guilloux
J
J
Service de neurologie de l'hôpital Avicenne, Assistance publique-Hôpitaux de Paris, 125, route de Stalingrad, 75013 Bobigny, France.
Carpentier
A-F
AF
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000628:therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D015398:Signal Transduction
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011480:Protease Inhibitors; D011505:Protein-Tyrosine Kinases